September 30, 2025 — Leads & Copy — BenchSci, a leader in AI solutions for preclinical research and drug discovery, has partnered with Thermo Fisher Scientific Inc. to deliver AI-powered research tools and digital capabilities. The collaboration aims to accelerate experimental design and improve R&D productivity for scientists.
The partnership will leverage BenchSci’s ASCEND™ AI technology to develop new AI-enabled tools, including enterprise software solutions for scientific and analytical instruments, web-based research literature search, and optimized reagent selection. These tools will help scientists interpret data, design experiments, review literature, and optimize resources.
Liran Belenzon, CEO and co-founder of BenchSci, stated that the partnership will expand research possibilities by pairing BenchSci’s AI expertise with Thermo Fisher’s lab equipment and services footprint.
Gianluca Pettiti, executive vice president and president at Thermo Fisher Scientific, noted that the partnership will help customers accelerate their work by combining global scale, products, and innovation with BenchSci’s AI capabilities, enabling faster and more cost-effective drug development.
BenchSci applies AI to understand disease biology, aiming to increase the speed and quality of R&D. Their ASCEND platform acts as an AI assistant for preclinical organizations. BenchSci has raised over $200 million from investors and supports science at top pharmaceutical companies and research centers.
Source: BenchSci
